CEVEC Pharmaceuticals GmbH, a Cologne, Germany-based biopharmaceutical company that specializes in developing and producing therapeutic proteins and monoclonal antibodies with human glycosylation patterns, closed a €4m financing round.
Creathor Venture Fonds and NRW.BANK led this round which included the participation from current investors and a group of private and institutional investors including the venture capital branch of Sparkasse KoelnBonn, and ERP Startfonds of KfW bank.
The funds will be used to continue the global commercialization of CEVEC’s proprietary CAP Technology platform, which is used for producing complex biologics and therapeutic antibodies with human-like glycosylation and sialylation patterns.
Commenting on the round, Dr. Rainer Lichtenberger, CEO of CEVEC, said: “We are delighted to have with Creathor Venture and NRW.BANK two first-class investors on board who value the unique strengths of the CAP Technology and provide the resources required to finance the company’s ambitious growth objectives”.
FinSMEs
04/11/2009